

2021 Financial Statements

These figures are extracted from the complete annual report 2021 of Stichting International Kidney Cancer Coalition in Ouder-Amstel as determined by the Board on April 04, 2022.

This annual report has been provided with an unqualified auditor's report, by Van Hoesel/De Blaey Accountancy B.V. on April 04, 2022.

Anne Wilson

Anne Wilson
Secretary/Treasurer

2. FINANCIAL STATEMENTS

Stichting International Kidney Cancer Coalition

2.1 Balance sheet as of 31 December 2021

(After result appropriation)

	31 December 2021		31 December 2020	
ASSETS	€	€	€	€
Current assets				
<i>Receivables</i>				
Other prepayments and accrued income	<u>52.936</u>	52.936	<u>88.174</u>	88.174
<i>Cash at bank and in hand</i>		1.192.753		868.061
Total assets		<u><u>1.245.689</u></u>		<u><u>956.235</u></u>

Stichting International Kidney Cancer Coalition

2.1 Balance sheet as of 31 December 2021

(After result appropriation)

	31 December 2021		31 December 2020	
	€	€	€	€
LIABILITIES				
Equity capital				
Restricted reserves	495.000		526.000	
Unrestricted reserves	<u>618.380</u>		<u>256.201</u>	
		1.113.380		782.201
Current liabilities				
Accounts payable	23.880		17.868	
Accrued liabilities	<u>108.429</u>		<u>156.166</u>	
		132.309		174.034
Total liabilities		<u><u>1.245.689</u></u>		<u><u>956.235</u></u>

2.2 Statement of income and expenditure 2021

	2021		2020	
	€	€	€	€
Income		687.755		663.618
Expenditure		356.576		453.117
Operating surplus		<u>331.179</u>		<u>210.501</u>

The amendment of reserves is divided as follows:

Restricted reserves World Kidney Cancer Day	141.058-	113.473-
Restricted reserves Global Kidney Cancer Summit	17.367-	33.424-
Restricted reserves PAG Incubator	-	-
Restricted reserves COVID-19	4.577-	-
Restricted reserves Dashboard Project	1.941-	2.637-
Restricted reserves Global Patient Survey Communications	8.470-	45.952-
Restricted reserves Clinical Trial Retention Problems	3.200-	-
Restricted reserves Decision Aid: Clinical Trials Basics	7.703-	-
Restricted reserves Global Patient Survey 2022	-	-
Restricted reserves Decision Aid: Clinical Trial Participation	-	-
The addition to the unrestricted reserves	<u>515.495</u>	<u>405.987</u>
Operating surplus	<u>331.179</u>	<u>210.501</u>

2.3 Cash flow statement 2021

The cash flow statement has been prepared according to the indirect method.

	2021		2020	
	€	€	€	€
Cash flow from operating activities				
Operating result		331.179		210.501
Change in working capital:				
Receivables	35.238		20.964-	
Current liabilities (except debts to credit institutions)	41.725-		10.529	
		6.487-		10.435-
Cash flow from IKCC operations		324.692		200.066
Cash flow from operating activities		324.692		200.066
Movements in cash		324.692		200.066
Notes to the cash resources				
Total by 1 January 2021		868.061		667.995
Movements in cash		324.692		200.066
Total by 31 December		1.192.753		868.061

2.4 Notes to the financial statements

General notes

Activities

The activities of Stichting International Kidney Cancer Coalition, having its registered office at Ouder-Amstel primarily consist of:

- The International Kidney Cancer Coalition (IKCC) is an independent international network of patient organisations that focus exclusively, or include a specific focus, on kidney cancer. It is legally incorporated as a Foundation in the Netherlands. The organisation was born from a very strong desire among various national kidney cancer patient groups to network, cooperate and share materials, knowledge and experiences. IKCC is governed by a volunteer Board of Directors with members from a minimum of four countries.

The actual activities are carried out at , Ouder-Amstel.

Registered office, legal form and registration number at the chamber of commerce

Stichting International Kidney Cancer Coalition, B31 has been registered at the Chamber of Commerce under file number 62070665.

Estimates

In applying the principles and policies for drawing up the financial statements, the management of the IKCC makes different estimates and judgments that may be essential to the amounts disclosed in the financial statements. If it is necessary in order to provide the transparency required under art. 362, sub 1, book 2 of the Dutch Civil Code the nature of these estimates and judgments, including related assumptions, is disclosed in the Notes to the relevant financial statement item.

General accounting policies

General

The financial statements are drawn up in accordance with the Richtlijnen voor de Jaarverslaggeving C1 Kleine Organisaties-zonder-winststreven (RJK C1).

The valuation of assets and liabilities and the determination of the result are based on historical costs. Unless stated otherwise in the respective basis for the specific balance sheet item, the assets and liabilities are valued according to the cost-price model.

Income and expenditure are allocated to the year to which they are related. Results are only included to the extent they have been achieved on the balance sheet date. Liabilities and potential losses originating before the end of the reporting year are taken into account if they are known before the preparation of the annual accounts.

Comparison with previous year

The valuation principles and method of determining the result are the same as those used in the previous year, with the exception of the changes in accounting policies as set out in the relevant sections.

Foreign currency

Functional currency

Items included in the financial statements of the Foundation are valued with due regard for the currency in the economic environment in which the Foundation carries out most of its activities (the functional currency). The financial statements are denominated in euros; this is both the functional currency and presentation currency of the Foundation.

2.4 Notes to the financial statements

Transactions, receivables and liabilities

Transactions in foreign currencies are stated in the financial statements at the exchange rate of the functional currency on the transaction date.

Monetary assets and liabilities in foreign currencies are converted to the closing rate of the functional currency on the balance sheet date. The translation differences resulting from settlement and conversion are credited or charged to the income statement, unless hedge-accounting is applied.

Non-monetary assets valued at historical cost in a foreign currency are converted at the exchange rate on the transaction date.

ACCOUNTING POLICIES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

Accounts receivable

The receivables are initially recognised at the fair value and subsequently valued at amortised costs. The fair value and amortised cost are equal to the nominal value. Provisions deemed necessary for the risk of bad debts are deducted. The provisions are determined based on individual assessment of the receivables.

Cash at banks and in hand

Cash at banks and in hand represent cash in hand, bank balances and deposits with terms of less than twelve months. Overdrafts at banks are recognised as part of debts to lending institutions under current liabilities. Cash at banks and in hand is carried at nominal value.

Current liabilities

On initial recognition current liabilities are recognised at fair value. After initial recognition current liabilities are recognised at the amortised cost price, being the amount received, taking into account premiums or discounts, less transaction costs. This usually is the nominal value.

Reserves

Unrestricted reserves

The Foundation has unrestricted reserves, which may be freely spent within the statutory objectives of the organisation. Amendments on the unrestricted reserves are done through the results allocation of the statement of income and expenditure.

Restricted Reserves

The Foundation has Restricted reserves, which have a more limited designation than the Unrestricted Reserves. The limitation of the reserves is imposed by the Board of Directors. Amendments on the Restricted reserves are done through the result allocation of the statement of income and expenditure.

2.4 Notes to the financial statements

PRINCIPLES FOR THE DETERMINATION OF THE RESULT

General

The surplus or deficit is determined as the difference between the total income and total expenses of the year to which they relate.

Income

The income of the Foundation is recorded and recognized in the period in which the income has been effectuated. The effectuation is determined based on the sponsorship period or the realization of events.

Expense

The expenses of the Foundation are determined on a historical basis and are attributed to the reporting year to which they relate.

PRINCIPLES FOR THE PREPARATION OF THE CASH-FLOW STATEMENT

Accounting policies for the cash flow statement

The cash flow statement is prepared according to the indirect method. The cash items disclosed in the cash flow statement comprise cash at bank and in hand. Cash flow denominated in foreign currencies have been translated at average estimated exchange rates.

Interest paid and received, dividends received and income taxes are included in cash from operating activities.

2.5 Notes to the balance sheet

ASSETS

CURRENT ASSETS

Receivables

	31-12-2021	31-12-2020
	€	€
Other prepayments and accrued income		
Costs paid up front	45.396	33.174
Amounts receivable	7.540	55.000
	<u>52.936</u>	<u>88.174</u>
 Cash at bank and in hand		
ING payment account	20.787	6.875
ING reserve operating account	150.100	150.185
ING US Dollar account	1.021.942	711.059
Creditcard	76-	58-
	<u>1.192.753</u>	<u>868.061</u>

2.5 Notes to the balance sheet

LIABILITIES

Foundation's capital

	2021	2020
	€	€
Restricted reserves World Kidney Cancer Day		
Value as of 1 January	120.000	120.000
Utilization	141.058-	113.473-
From unrestricted reserves	141.058	113.473
Value as of 31 December	120.000	120.000

	2021	2020
	€	€
Restricted reserves Global Kidney Cancer Summit		
Value as of 1 January	116.000	116.000
Utilization	17.367-	33.424-
From unrestricted reserves	17.367	33.424
Value as of 31 December	116.000	116.000

	2021	2020
	€	€
Restricted reserves PAG Incubator		
Value as of 1 January	100.000	-
Utilization	-	-
From unrestricted reserves	-	100.000
Value as of 31 December	100.000	100.000

	2021	2020
	€	€
Restricted reserves COVID-19		
Value as of 1 January	45.000	-
Utilization	4.577-	-
To unrestricted reserves	40.423-	45.000
Value as of 31 December	-	45.000

	2021	2020
	€	€
Restricted reserves Dashboard Project		
Value as of 1 January	44.000	44.000
Utilization	1.941-	2.637-
From unrestricted reserves	1.941	2.637
Value as of 31 December	44.000	44.000

2.5 Notes to the balance sheet

	2021	2020
	€	€
Restricted reserves Global Patient Survey Communications		
Value as of 1 January	42.000	85.000
Utilization	8.470-	45.952-
To unrestricted reserves	33.530-	2.952
Value as of 31 December	-	42.000

	2021	2020
	€	€
Restricted reserves Clinical Trial Retention Problems		
Value as of 1 January	39.000	-
Utilization	3.200-	-
To unrestricted reserves	35.800-	39.000
Value as of 31 December	-	39.000

	2021	2020
	€	€
Restricted reserves Decision Aid: Clinical Trials Basics		
Value as of 1 January	20.000	-
Utilization	7.703-	-
To unrestricted reserves	12.297-	20.000
Value as of 31 December	-	20.000

	2021	2020
	€	€
Restricted reserves Global Patient Survey 2022		
Value as of 1 January	-	-
Utilization	-	-
From unrestricted reserves	90.000	-
Value as of 31 December	90.000	-

	2021	2020
	€	€
Restricted reserves Decision Aid: Clinical Trial Participation		
Value as of 1 January	-	-
Utilization	-	-
From unrestricted reserves	25.000	-
Value as of 31 December	25.000	-

2.5 Notes to the balance sheet

	2021	2020
	€	€
Unrestricted reserves		
Value as of 1 January	256.201	206.700
To restricted reserves	153.316-	356.486-
Operating result	515.495	405.987
Value as of 31 December	<u>618.380</u>	<u>256.201</u>
CURRENT LIABILITIES		
	31-12-2021	31-12-2020
	€	€
Accounts payable		
Creditors	<u>23.880</u>	<u>17.868</u>
Accrued liabilities		
Amounts received in advance	84.600	141.255
Payable costs	23.829	14.911
	<u>108.429</u>	<u>156.166</u>

2.6 Notes to the statement of income and expenditure

Income

Sustaining partnerships	163.239	179.060
Projects	<u>524.516</u>	<u>484.558</u>
	<u><u>687.755</u></u>	<u><u>663.618</u></u>

<u>2021</u>	<u>2020</u>
€	€

Expenditure

Objective 1: To strengthen the capacity of current and emerging affiliates in their support for patients with kidney cancer.	49.154	77.384
Objective 2: To advocate for access to best care	78.201	116.698
Objective 3: To increase awareness of kidney cancer globally	164.328	157.433
Objective 4: To be a global authority in the provision of credible and up-to-date kidney cancer information.	39.643	61.494
Objective 5: To foster projects promoting the voice of kidney cancer patients in research activities worldwide	25.250	40.108
	<u><u>356.576</u></u>	<u><u>453.117</u></u>